MedTrace Logo

Investigation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LIM-0705 in Male Subjects With Impaired Glucose Tolerance

NCT01093677 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2010-06-08

No results posted yet for this study

Summary

LIM-0705 will gain results on the effects of LIM-0705 on Male Subjects with Impaired Glucose Tolerance

Conditions

  • Impaired Glucose Tolerance

Interventions

DRUG

LIM-0705

Oral solution 750 mg LIM 0705 BID for 14 days.

DRUG

Placebo

Oral solution placebo BID for 14 days.

Sponsors & Collaborators

  • Limerick BioPharma

    lead INDUSTRY

Principal Investigators

  • Albert Frauman, MD · Nucleus Network

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2010-06-30
Completion
2010-07-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01093677 on ClinicalTrials.gov